Shu‐Hui Lv

562 total citations
19 papers, 175 citations indexed

About

Shu‐Hui Lv is a scholar working on Otorhinolaryngology, Oncology and Surgery. According to data from OpenAlex, Shu‐Hui Lv has authored 19 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Otorhinolaryngology, 10 papers in Oncology and 6 papers in Surgery. Recurrent topics in Shu‐Hui Lv's work include Head and Neck Cancer Studies (14 papers), Lung Cancer Treatments and Mutations (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Shu‐Hui Lv is often cited by papers focused on Head and Neck Cancer Studies (14 papers), Lung Cancer Treatments and Mutations (4 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Shu‐Hui Lv collaborates with scholars based in China and United States. Shu‐Hui Lv's co-authors include Wei‐Xiong Xia, Yan‐Qun Xiang, Wang‐Zhong Li, Hu L, Guoying Liu, Xiang Guo, Xing Lv, Nian Lu, Meng‐Yun Qiang and Meifu Gan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Shu‐Hui Lv

15 papers receiving 174 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu‐Hui Lv China 8 125 97 71 42 32 19 175
Wei-Xiong Xia China 5 127 1.0× 101 1.0× 64 0.9× 43 1.0× 37 1.2× 5 173
Laura Sala Italy 5 144 1.2× 123 1.3× 118 1.7× 22 0.5× 19 0.6× 10 223
Sarin Kitpanit Thailand 9 148 1.2× 77 0.8× 62 0.9× 99 2.4× 16 0.5× 22 216
Enya H.W. Ong Singapore 7 111 0.9× 58 0.6× 53 0.7× 70 1.7× 34 1.1× 20 162
Hao‐Jun Xie China 11 150 1.2× 114 1.2× 97 1.4× 100 2.4× 31 1.0× 19 239
Yan-Fang Ye China 7 101 0.8× 76 0.8× 47 0.7× 44 1.0× 28 0.9× 7 167
N Moeckelmann Germany 4 171 1.4× 96 1.0× 110 1.5× 33 0.8× 24 0.8× 5 228
Shie-Lee Cheah United Kingdom 4 165 1.3× 84 0.9× 119 1.7× 69 1.6× 11 0.3× 4 193
Chun‐Ta Liao Taiwan 6 250 2.0× 129 1.3× 190 2.7× 64 1.5× 18 0.6× 8 311
Marzia Franceschini Italy 6 157 1.3× 65 0.7× 110 1.5× 67 1.6× 39 1.2× 15 220

Countries citing papers authored by Shu‐Hui Lv

Since Specialization
Citations

This map shows the geographic impact of Shu‐Hui Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu‐Hui Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu‐Hui Lv more than expected).

Fields of papers citing papers by Shu‐Hui Lv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu‐Hui Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu‐Hui Lv. The network helps show where Shu‐Hui Lv may publish in the future.

Co-authorship network of co-authors of Shu‐Hui Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Shu‐Hui Lv. A scholar is included among the top collaborators of Shu‐Hui Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu‐Hui Lv. Shu‐Hui Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Li, Wang‐Zhong, Ying Huang, Xiaobin Zhu, et al.. (2024). Single‐cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma. Clinical and Translational Medicine. 14(10). e70061–e70061. 2 indexed citations
3.
4.
Lv, Shu‐Hui, et al.. (2023). Benign thyroid nodules classified as ACR TI-RADS 4 or 5: Imaging and histological features. European Journal of Radiology. 175. 111261–111261. 2 indexed citations
5.
Chen, Xi, et al.. (2023). Vision based defect detection technologies in civil structures: a review study. Journal of Optics. 53(2). 1456–1461.
6.
Li, Wang‐Zhong, Shu‐Hui Lv, Guoying Liu, et al.. (2023). Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma. Frontiers in Immunology. 14. 1124066–1124066.
7.
8.
Li, Wang‐Zhong, Shu‐Hui Lv, Guoying Liu, et al.. (2021). Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. Biology of Sex Differences. 12(1). 18–18. 20 indexed citations
9.
Li, Wang‐Zhong, Xin Hua, Shu‐Hui Lv, et al.. (2021). A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. Journal of Inflammation Research. Volume 14. 817–828. 14 indexed citations
10.
Lv, Shu‐Hui, Wang‐Zhong Li, Hu L, et al.. (2021). Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy. Journal of Inflammation Research. Volume 14. 2225–2237. 5 indexed citations
11.
Liu, Guoying, Wang‐Zhong Li, De‐Shen Wang, et al.. (2021). Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.. Journal of Clinical Oncology. 39(15_suppl). 6044–6044. 3 indexed citations
12.
Li, Wang‐Zhong, Haijun Wu, Shu‐Hui Lv, et al.. (2021). Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus–Related Nasopharyngeal Carcinoma. JAMA Network Open. 4(9). e2124721–e2124721. 20 indexed citations
13.
Li, Wang‐Zhong, Shu‐Hui Lv, Hu L, et al.. (2020). Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors. SHILAP Revista de lepidopterología. 10(3). e134–e134. 1 indexed citations
14.
Li, Wang‐Zhong, Shu‐Hui Lv, Guoying Liu, et al.. (2020). Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. International Journal of Radiation Oncology*Biology*Physics. 109(1). 120–130. 32 indexed citations
15.
Li, Wang‐Zhong, Guoying Liu, Shu‐Hui Lv, et al.. (2020). MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it. Radiotherapy and Oncology. 145. 101–108. 14 indexed citations
16.
Chen, Xi, Xun Cao, Bingzhong Jing, et al.. (2020). Prognostic and Treatment Guiding Significance of MRI-Based Tumor Burden Features and Nodal Necrosis in Nasopharyngeal Carcinoma. Frontiers in Oncology. 10. 537318–537318. 7 indexed citations
17.
Li, Wang‐Zhong, Kangqiang Peng, Xing Lv, et al.. (2019). Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma. Cancer Medicine. 9(3). 920–930. 5 indexed citations
18.
L, Hu, Xing Lv, Lin Wang, et al.. (2018). The plasma Epstein–Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Therapeutic Advances in Medical Oncology. 10. 3861397371–3861397371. 12 indexed citations
19.
Lv, Shu‐Hui, et al.. (2011). Inflammatory myofibroblastic tumor of the rectum in a 13-month-old girl: a case report. Journal of Pediatric Surgery. 46(7). e1–e4. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wei-Xiong Xia Breakdown of academic impact, for papers by Laura Sala Breakdown of academic impact, for papers by Sarin Kitpanit Breakdown of academic impact, for papers by Enya H.W. Ong Breakdown of academic impact, for papers by Hao‐Jun Xie Breakdown of academic impact, for papers by Yan-Fang Ye Breakdown of academic impact, for papers by N Moeckelmann Breakdown of academic impact, for papers by Shie-Lee Cheah Breakdown of academic impact, for papers by Chun‐Ta Liao Breakdown of academic impact, for papers by Marzia Franceschini
Rankless by CCL
2026